TABLE 1.

Patient characteristics and outcomes

Patient	Tx organ	Age (y)/gender	BMI	Transplant indication	MELD/eGFR on day Tx	COVID-19 severity	Interval positive PCR and Tx (d)	Follow-up after Tx (d)	Post-Tximmunosuppression	Alive/functioning graft at last follow-up	Allograft rejection/reinfection
1	Liver	67/M	21	ICU cholangiopathy	20/92	Critical: ARDS for which ICU admission with invasive ventilation, ECMO, and dialysis	167	226	<3 m: BM + Tac + MMF>3 m: Tac + MMF	Yes/yes	No/no
2	Liver	68/M	29	NASH and HCC	10/93	Asymptomatic	169	148	<3 m: BM + Tac + MMF + MP>3 m: Tac + MMF	Yes/yes	No/no
3	Liver	50/F	27	AIH and PBC	25/116	Critical: ARDS for which ICU admission with invasive ventilation	195	156	<3 m: BM + Tac + MMF + MP>3 m: Tac + MMF	Yes/yes	No/no
4	Liver	57/F	36	ALD and HCC	17/87	Mild: anosmia and loss of taste, no hospitalization	26	95	<3 m: BM + Tac + MMF + MP>3 m: Tac + MMF	Yes/yes	No/no
5	Liver	52/F	26	Decompensated ALD	31/123	Mild: cough and myalgia, no hospitalization	60	65	<3 m: BM + Tac + MMF + MP	Yes/yes	No/no
6	Liver + kidney	72/F	22	ADPKD and ESKD	23/9	Asymptomatic	56	233	<3 m: BM + Tac + MMF + MP>3 m: Tac + MP	Yes/yes	No/no
7	Liver + kidney	69/M	25	ICU cholangiopathy and kidney failure	19/52	Critical: ARDS for which ICU admission with invasive ventilation, ECMO, dialysis, and MARS	148	38	<3 m: BM + Tac + MMF	No/no	No/no
8	Liver + kidney	63/M	28	NASH and hepatorenal syndrome	45/17	Asymptomatic	47	30	<3 m: BM + Tac + MMF + MP	Yes/yes	No/no
9	Kidney	69/M	30	Dent’s disease	–/6	Severe: loss of taste, anorexia, nausea, dyspnea with hospitalization, and noninvasive O2 supply	246	151	<3 m: Tac + MMF + MP>3 m: Tac + MMF + MP	Yes/yes	No/no
10	Kidney	62/M	35	Nephroangiosclerosis	–/6	Asymptomatic	49	270	<3 m: Tac + MMF + MP>3 m: Tac + MMF	Yes/yes	No/no
11	Kidney	61/M	30	Hypertensive nephropathy	–/16	Critical: ARDS for which ICU admission with invasive ventilation	339	10	<3 m: Tac + MMF + MP	Yes/yes	No/no

ADPKD, autosomal dominant polycystic kidney disease; AIH, autoimmune hepatitis; ALD, alcohol-related liver disease; ARDS, acute respiratory distress syndrome; BM, basiliximab; BMI, body mass index; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate in mL/min/1.73 m² (Chronic Kidney Disease Epidemiology Collaboration); ESKD, end-stage kidney disease; HCC, hepatocellular carcinoma; ICU, intensive care unit; MARS, molecular adsorbent recirculating system; MELD, model of end-stage liver disease; MMF, mycophenolate mofetil; MP, methylprednisolone; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cell; Tac, tacrolimus; Tx, transplantation; <3 m, within first 3 mo after Tx; >3 m, beyond 3 mo after Tx.